Lactic acid peeling in the treatment of epidermal melasma
DOI:
https://doi.org/10.66344/jpad.v28i2.1235Keywords:
Lactic acid peeling, melasma, efficacyAbstract
Objective To determine the efficacy of lactic acid peeling in the treatment of melasma.
Methods This quasi- experimental study was carried out at department of Dermatology, Sir Ganga Ram Hospital, Lahore. A total number of 40 patients, with age ranging from 20-50 years were included in the study. All patients were female except 2. All patients underwent lactic acid peeling sessions at 3 weekly intervals for a total 6 sessions. The severity of melasma was assessed by MASI score. Efficacy was based on mean decrease in MASI score at baseline and MASI score three weeks after the completion of treatment.
Results Mean of MASI scores of all these subjects at baseline was 12.62, and the mean MASI score recorded at the final follow-up was 6.30. Mean decrease in MASI scores was 6.32.
Conclusion Lactic acid peeling is effective in the treatment of epidermal type of facial melasma in Asian skin.
References
1. Gupta AK, Gover MD. The treatment of melasma: A review of clinical trials. J Am Acad Dermatol. 2006;55:1048-65.
2. Sarkar R, Puri P, Jain RK, Singh A, Desai A. Melasma in men: a clinical, aetiological and histological study. J Eur Acad Dermatol Venereol. 2010;24:768-72.
3. Ortonne JP, Arellano I, Berneburg M, Cestari T, Chan H, Grimes P et al. A global survey of the role of ultraviolet radiation and hormonal influences in the development of melasma. J Eur Acad Dermatol Venereol. 2009;23:1254-62.
4. Rendon M, Burneberg M, Arellano I, Picardo M. Treatment of melasma. J Am Acad Dermatol. 2006;54:272-81.
5. Wendy ER. Melasma. In: Kelly AP, Taylor SC, editors. Dermatology for Skin of Color. New York: McGraw-Hill Medical; 2009. p. 332-36.
6. Guinot C, Cheffai S, Latreille J, Dhaoui MA, Youssef S, Jaber K et al. Aggravating factors for melasma: a prospective study in 197 Tunisian patients. J Eur Acad Dermatol Venereol. 2010;24:1060-9.
7. Josefina NS, Juan PC, Bertha TA, Oros-Ovalle C, Fuentes-Ahumada C, González FJ et al. A double-blind, randomized clinical trial of niacinamide 4% versus hydroquinone 4% in the treatment of melasma. Dermatol Res Prac. 2011;2011:1-5.
8. Siddique MR, Khondker L, Hazra SC, Khan MSI. The efficacy of combination of 20 % azelaic acid with 0.05 % tretinoin cream in the treatment of melasma. J Pak Assoc Dermatol. 2011;21:265-9.
9. Hwang SW, Oh DJ, Lee D, Kim JW, Park SW. Clinical efficacy of 25% l-ascorbic acid (C’ensil) in the treatment of melasma. J Cutan Med Surg. 2009;13:74-81.
10. Rashmi S, Shikha C, Vijay KG. Newer and upcoming therapies for melasma. Indian J Dermatol Venereol Leprol. 2012;78:417-28.
11. Sailesh K, Aanand NG, Rebat MH. New horizons in treating disorders of hyperpigmentation in skin of color. Semin Cutan Med Surg. 2012;31:133-9.
12. Alvin G, Catambay N, Vergara A, Jamora MJ. A comparative study of the safety and efficacy of 75% mulberry (Morus alba) extract oil versus placebo as a topical treatment for melasma: A randomized, single-blind, placebo controlled trial. J Drugs Dermatol. 2011;10:1025-31.
13. Altaei T. The treatment of melasma by silymarin cream. BMC Dermatol. 2012;12:18.
14. Malek J, Chedraoui A, Nikolic D, Barouti N, Ghosn S, Abbas O. Successful treatment of hydroquinone-resistant melasma using topical methimazole. Dermatol Ther. 2013;26:69-72.
15. Yenny SY, Lestari W. A study comparing the use of 10% L-ascorbic acid and 10% zinc sulfate solution in the treatment of melasma. Malay J Dermatol. 2012;29:38-45.
16. Arielle NB, Kauvar. The evolution of melasma therapy: targeting melanosomes using low fluence Q-switched neodymium-doped yttrium aluminum garnet lasers. Semin Cutan Med Surg. 2012;31:126-32.
17. Kroon MW, Wind BS, Beek JF, van der Veen JP, Nieuweboer-Krobotová L, Bos JD et al. Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma: A randomized controlled pilot study. J Am Acad Dermatol. 2011;64:516-23.
18. Karsai S, Fischer T, Pohl L, Schmitt L, Buhck H, Jünger M et al. Is non-ablative 1550-nm fractional photothermolysis an effective modality to treat melasma? Results from a prospective controlled single-blinded trial in 51 patients. J Eur Acad Dermatol Venereol. 2012;26:470-76.
19. Lee HI, Lim YY, Kim BJ, Kim MN, Min HJ, Hwang JH et al. Clinicopathologic efficacy of copper bromide plus/Yellow laser (578nm with 511nm) for treatment of melasma in Asian patients. Dermatol Surg. 2010;36:885-93.
20. Wanitphakdeedecha R, Manuskiatti W, Siriphukpong S, Chen TM. Treatment of melasma using variable square pulse Er:YAG laser resurfacing. Dermatol Surg. 2009;35:475-81.
21. Polnikorn N. Treatment of refractory melasma with the MedLite C6 Q-switched Nd:YAG laser and alpha arbutin: A prospective study. J Cosmet Laser Ther. 2010;12:126-31.
22. Suh KS, Sung JY, Roh HJ, Jeon YS, Kim YC, Kim ST. Efficacy of the 1064-nm Q-switched Nd: YAG laser in melasma. J Dermatolog Treat. 2011;22:233-38.
23. Wattanakrai P, Mornchan R, Eimpunth S. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1064 nm) laser for the treatment of facial melasma in Asians. Dermatol Surg. 2010;36:76-87.
24. Prignano F, Ortonne JP, Buggiani G, Lotti T. Therapeutic approaches to melasma. Dermatol Clin. 2007;25:337-42.
25. Usuki A, Ohashi A, Sato H, Ochiai Y, Ichihashi M, Funasaka Y. The inhibitory effects of glycolic acid and lactic acid on melanin synthesis in melanoma cells. Exp Dermatol. 2003;12:43-50.
26. Sharquie KE, Al-Tikreety MM, Al-Mashhadani SA. Lactic acid as a new therapeutic peeling agent in melasma. Dermatol Surg. 2005;31:149-54.
27. Sharquie KE, Al-Tikreety MM, Al-Mashhadani SA. Lactic acid chemical peels as a new therapeutic modality in melasma in comparison to Jessner’s solution chemical peels. Dermatol Surg. 2006;32:1429-36.
28. Ejaz A, Raza N, Iftikhar N, Muzaffar F. Comparison of 30% salicylic acid with Jessner’s solution for superficial chemical peeling in epidermal melasma. J Coll Physicians Surg Pak. 2008;18:205-8.
Downloads
Published
Issue
Section
License
Copyright (c) 2018 Saadiya Siddiqui, Tariq Rashid
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
